Who Qualifies for GLP-1 Medication Without Obesity Diagnosis Individuals with prediabetes, type 2 diabetes, or cardiovascular risk factors may be appropriate candidates for GLP-1 therapy regardless of BMI
Early gastroparesis symptoms: acid reflux, heartburn, nausea and vomiting, abdominal distension or bloating, early satiety (getting full after only a few bites) Early kidney dysfunction-proteinuria, swelling of extremities (hands and feet), increased fatigue, and weakness
Optimal outcomes depend on quality sourcing, proper reconstitution and injection technique, consistent monitoring, and integration with nutrition, exercise, sleep, and stress-management strategies
One common concern is whether these injections can cause stomach ulcers